Completed PHASE3 INTERVENTIONAL 1-arm NCT02110147

Open-Label Study of Uridine Triacetate in Pediatric Patients With Hereditary Orotic Aciduria

Sponsor: Wellstat Therapeutics

Updated 9 times since 2017 Last updated: Jun 29, 2017 Started: Apr 30, 2014 Primary completion: Dec 31, 2014 Completion: Sep 8, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Hereditary Orotic Aciduria, this trial is completed. The trial is conducted by Wellstat Therapeutics and has accumulated 9 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2023 — Jul 2024 [monthly]

Completed PHASE3
Dec 2022 — Jan 2023 [monthly]

Completed PHASE3
Jan 2021 — Dec 2022 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Aug 2017 — Jun 2018 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed · Phase: PHASE2 → PHASE3
Feb 2017 — Aug 2017 [monthly]

Active Not Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE2

First recorded

Apr 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Wellstat Therapeutics

Data source: Wellstat Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Detroit, United States
• Pittsburgh, United States